ijms-logo

Journal Browser

Journal Browser

Recent Progress in the Development of Anticancer Prodrugs

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: closed (31 May 2021) | Viewed by 3991

Special Issue Editor


E-Mail Website
Guest Editor
Department of Biological Chemistry and Bioimaging, Wroclaw University of Science and Technology, 50-370 Wroclaw, Poland
Interests: proteases; mass cytometry; cancer prodrugs; activity-based probes; caspases; cell death; unnatural amino acids; enzymes imaging; biological chemistry

Special Issue Information

Dear Colleagues,

Cancer is undoubtedly among the most complex systems in biology, and despite the significant research effort that has been made in several past decades, this disease is still responsible for millions of deaths worldwide. The overall success of cancer treatment is dependent on the combination of early diagnosis, accurate patient stratification and the selection of personalized treatment. Current treatment options for cancer include chemotherapy, surgery, radiation and immunotherapy. Nowadays one of the most promising chemotherapeutic strategy to combat cancer are prodrugs. This system enables the precise delivery of the cargo (drug, toxic payload) to the cancer cells, and the release of free drug upon intra-tumoral internalization or within tumor microenvironment.

This special issue of the International Journal of Molecular Sciences entitled “Recent Progress in the Development of Anticancer Prodrugs” will focus on recent chemical- and biological-based strategies for the development of new treatment options for cancer, including antibody-drug conjugates, peptide-drug conjugates, pro-antibodies, aptamer-drug conjugates, nanomaterials and more. Therefore, the aim of this issue is to present the structural and mechanistic aspects of modern anticancer prodrugs, their biological and clinical efficacy, as well as the ongoing efforts focusing on optimizing prodrug structures in terms of targeted delivery, conjugation chemistry, linkers technology and payloads potency. Contributions on these topics are welcome, including original research and reviews.

Dr. Marcin Poreba
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer therapy
  • targeted therapy
  • prodrugs
  • antibody-drug conjugates
  • peptide-drug conjugates
  • aptamer-drug conjugates
  • pro-antibodies
  • enzymes
  • proteases
  • personalized medicine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

23 pages, 7167 KiB  
Article
Synthesis of Novel Acyl Derivatives of 3-(4,5,6,7-Tetrabromo-1H-benzimidazol-1-yl)propan-1-ols—Intracellular TBBi-Based CK2 Inhibitors with Proapoptotic Properties
by Konrad Chojnacki, Patrycja Wińska, Olena Karatsai, Mirosława Koronkiewicz, Małgorzata Milner-Krawczyk, Monika Wielechowska, Maria Jolanta Rędowicz, Maria Bretner and Paweł Borowiecki
Int. J. Mol. Sci. 2021, 22(12), 6261; https://doi.org/10.3390/ijms22126261 - 10 Jun 2021
Cited by 8 | Viewed by 3307
Abstract
Protein kinase CK2 has been considered as an attractive drug target for anti-cancer therapy. The synthesis of N-hydroxypropyl TBBi and 2MeTBBi derivatives as well as their respective esters was carried out by using chemoenzymatic methods. Concomitantly with kinetic studies toward recombinant CK2, [...] Read more.
Protein kinase CK2 has been considered as an attractive drug target for anti-cancer therapy. The synthesis of N-hydroxypropyl TBBi and 2MeTBBi derivatives as well as their respective esters was carried out by using chemoenzymatic methods. Concomitantly with kinetic studies toward recombinant CK2, the influence of the obtained compounds on the viability of two human breast carcinoma cell lines (MCF-7 and MDA-MB-231) was evaluated using MTT assay. Additionally, an intracellular inhibition of CK2 as well as an induction of apoptosis in the examined cells after the treatment with the most active compounds were studied by Western blot analysis, phase-contrast microscopy and flow cytometry method. The results of the MTT test revealed potent cytotoxic activities for most of the newly synthesized compounds (EC50 4.90 to 32.77 µM), corresponding to their solubility in biological media. We concluded that derivatives with the methyl group decrease the viability of both cell lines more efficiently than their non-methylated analogs. Furthermore, inhibition of CK2 in breast cancer cells treated with the tested compounds at the concentrations equal to their EC50 values correlates well with their lipophilicity since derivatives with higher values of logP are more potent intracellular inhibitors of CK2 with better proapoptotic properties than their parental hydroxyl compounds. Full article
(This article belongs to the Special Issue Recent Progress in the Development of Anticancer Prodrugs)
Show Figures

Figure 1

Back to TopTop